In the SURMOUNT-1 clinical trial, patients taking the highest dose (15 mg) of tirzepatide lost about 21% of their body weight over 72 weeks
Given that amylin signalling is a key therapeutic target for next-generation weight-loss drugs, amylin receptor agonists such as pramlintide, cagrilintide and KBP-066 also warrant consideration as to metabolism and detection strategies in sports drug testing programs
Peak symptoms & resolution timeline Clinical data shows that GI side effects like diarrhea peak around week 20 of treatment, then decline significantly thereafter
Pricing is $289/mo month-to-month, or from $249/mo on the 6-month plana transparent, flat rate that remains constant regardless of dose adjustments
Tirzepatide may also be prescribed among individuals who are overweight, with a BMI of 27 or higher, if they have other health issues that are associated with their being overweight